

## OneSource Specialty Pharma strengthens Board by appointing three new Independent Directors

06 March 2025 | News

**Directors bring decades of leadership experience and expertise in pharma, and business strategy**



OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, has announced the appointment of three new non-executive independent directors to its Board — Dr Claudio Albrecht, Debarati Sen and Vijay Karwal—effective February 27, 2025.

The directors bring decades of leadership experience and expertise in Pharma, Business Strategy, Transformation, Merger & Acquisition (M&A) among others. These appointments align with the group's philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance.

Dr Claudio Albrecht is a pharmaceutical industry veteran with over 30 years of experience. He co-founded Albrecht, Prock & Partners and previously served as CEO of STADA AG, Actavis Group, and Ratiopharm Group. He serves as an Independent Director on the Board of Dr. Reddy's Laboratories. He has led significant internationalization and turnaround strategies, including driving Ratiopharm's biosimilars program and orchestrating Actavis's \$6 billion sale to Watson. Dr Albrecht holds a PhD in law and has a deep understanding of pharmaceutical strategy and global market dynamics.

Debarati Sen is a seasoned global business leader with a track record of driving transformative business performance. Currently the Group President at HMTX Industries, she has led growth and strategic initiatives across industrial and consumer businesses, including heading the largest division in 3M's Consumer Business Group with brands like Filtrete, Command, and ScotchBlue. She previously served as CEO and Managing Director of 3M India Ltd. and is an active leader in non-profit and academic boards, including the Women's Foundation of Minnesota and the Carlson School of Management.

Vijay Karwal is a Managing Director at CBC Group, Asia's largest healthcare-dedicated asset management firm, where he is focused on capital deployment and portfolio management for the firm's private equity and royalty & private credit investment funds. With over 25 years of global experience, he has held industry leadership roles at AffaMed Therapeutics and DaVita Inc., and senior investment banking roles with Nomura, CIMB, RBS, and ABN AMRO. He also serves as an Independent

Director of Mega Lifesciences PCL and brings a wealth of expertise in healthcare investments and strategic growth initiatives.